Literature DB >> 16014954

Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps.

Joshua C Grieger1, Richard J Samulski.   

Abstract

The limited packaging capacity of adeno-associated virus (AAV) precludes the design of vectors for the treatment of diseases associated with larger genes. Autonomous parvoviruses, such as minute virus of mice and B19, while identical in size (25 nm), are known to package larger genomes of 5.1 and 5.6 kb, respectively, compared to AAV genomes of 4.7 kb. One primary difference is the fact that wild-type (wt) AAV utilizes three capsid subunits instead of two to form the virion shell. In this study, we have characterized the packaging capacity of AAV serotypes 1 through 5 with and without the Vp2 subunit. Using reporter transgene cassettes that range in size from 4.4 to 6.0 kb, we determined that serotypes 1 through 5 with and without Vp2 could successfully package, replicate in, and transduce cells. Dot blot analysis established that packaging efficiency was similar for all vector cassettes and that the integrity of encapsidated genomes was intact regardless of size. Although physical characterization determined that virion structures were indistinguishable from wt, transduction experiments determined that all serotype vectors carrying larger genomes (5.3 kb and higher) transduced cells less efficiently (within a log) than AAV encapsidating wt size genomes. This result was not unique to reporter genes and was observed for CFTR vector cassettes ranging in size from 5.1 to 5.9 kb. No apparent advantage in packaging efficiency was observed when Vp2 was present or absent from the virion. Further analysis determined that a postentry step was responsible for the block in infection and specific treatment of cells upon infection with proteasome inhibitors increased transduction of AAV encapsidating larger DNA templates to wt levels, suggesting a preferential degradation of virions encapsidating larger-than-wt genomes. This study illustrates that AAV is capable of packaging and protecting recombinant genomes as large as 6.0 kb but the larger genome-containing virions are preferentially degraded by the proteasome and that this block can be overcome by the addition of proteasome inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014954      PMCID: PMC1181570          DOI: 10.1128/JVI.79.15.9933-9944.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts.

Authors:  J Hansen; K Qing; A Srivastava
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization.

Authors:  L Sun; J Li; X Xiao
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

3.  A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation.

Authors:  D Duan; Y Yue; Z Yan; J F Engelhardt
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

4.  Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy.

Authors:  Z Yan; Y Zhang; D Duan; J F Engelhardt
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

5.  Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.

Authors:  Joseph E Rabinowitz; Fabienne Rolling; Chengwen Li; Hervè Conrath; Weidong Xiao; Xiao Xiao; R Jude Samulski
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection.

Authors:  Yuji Kashiwakura; Kenji Tamayose; Kazuhisa Iwabuchi; Yukihiko Hirai; Takashi Shimada; Kunio Matsumoto; Toshikazu Nakamura; Masami Watanabe; Kazuo Oshimi; Hiroyuki Daida
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids.

Authors:  S Kronenberg; J A Kleinschmidt; B Böttcher
Journal:  EMBO Rep       Date:  2001-11       Impact factor: 8.807

8.  The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity.

Authors:  Anne Girod; Christiane E Wobus; Zoltán Zádori; Martin Ried; Kristin Leike; Peter Tijssen; Jürgen A Kleinschmidt; Michael Hallek
Journal:  J Gen Virol       Date:  2002-05       Impact factor: 3.891

9.  A viral phospholipase A2 is required for parvovirus infectivity.

Authors:  Z Zádori; J Szelei; M C Lacoste; Y Li; S Gariépy; P Raymond; M Allaire; I R Nabi; P Tijssen
Journal:  Dev Cell       Date:  2001-08       Impact factor: 12.270

10.  Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors.

Authors:  Ziying Yan; Roman Zak; G W Gant Luxton; Teresa C Ritchie; Ursula Bantel-Schaal; John F Engelhardt
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

View more
  143 in total

1.  The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer's disease.

Authors:  Megan M Varnum; Tomomi Kiyota; Kaitlin L Ingraham; Seiko Ikezu; Tsuneya Ikezu
Journal:  Neurobiol Aging       Date:  2015-08-01       Impact factor: 4.673

2.  Mechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors.

Authors:  Angela M Mitchell; R Jude Samulski
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

3.  Synthetic intron improves transduction efficiency of trans-splicing adeno-associated viral vectors.

Authors:  Yi Lai; Yongping Yue; Mingju Liu; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2006-10       Impact factor: 5.695

4.  CRISPR-Mediated Integration of Large Gene Cassettes Using AAV Donor Vectors.

Authors:  Rasmus O Bak; Matthew H Porteus
Journal:  Cell Rep       Date:  2017-07-18       Impact factor: 9.423

Review 5.  Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.

Authors:  Majid Lotfinia; Meghdad Abdollahpour-Alitappeh; Behzad Hatami; Mohammad Reza Zali; Morteza Karimipoor
Journal:  Clin Exp Med       Date:  2019-05-03       Impact factor: 3.984

Review 6.  Gene therapy to treat cardiac arrhythmias.

Authors:  Rossana Bongianino; Silvia G Priori
Journal:  Nat Rev Cardiol       Date:  2015-04-28       Impact factor: 32.419

7.  Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals.

Authors:  A Asokan; J S Johnson; C Li; R J Samulski
Journal:  Gene Ther       Date:  2008-07-31       Impact factor: 5.250

8.  Characterization of genome integrity for oversized recombinant AAV vector.

Authors:  Biao Dong; Hiroyuki Nakai; Weidong Xiao
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

9.  Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb.

Authors:  Yi Lai; Yongping Yue; Dongsheng Duan
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

10.  Effect of genome size on AAV vector packaging.

Authors:  Zhijian Wu; Hongyan Yang; Peter Colosi
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.